CTLA4 and neoplasm: Specifically, dual PD-1 and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibition, when administered with a FasL-neutralizing antibody, results in a significantly greater reduction in tumor burden than checkpoint blockade alone [139, 189].